These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12527996)

  • 41. [Histochemical findings of and fine structural changes in motor endplates in diseases with neuromuscular transmission abnormalities].
    Yoshimura T; Motomura M; Tsujihata M
    Brain Nerve; 2011 Jul; 63(7):719-27. PubMed ID: 21747142
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis.
    Sahashi K; Engel AG; Lambert EH; Howard FM
    J Neuropathol Exp Neurol; 1980 Mar; 39(2):160-72. PubMed ID: 7373347
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The human-severe combined immunodeficiency myasthenic mouse model: a new approach for the study of myasthenia gravis.
    Martino G; DuPont BL; Wollmann RL; Bongioanni P; Anastasi J; Quintans J; Arnason BG; Grimaldi LM
    Ann Neurol; 1993 Jul; 34(1):48-56. PubMed ID: 8517679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myasthenic patients' IgG causes redistribution of acetylcholine receptors: freeze-fracture studies.
    Pumplin DW; Drachman DB
    J Neurosci; 1983 Mar; 3(3):576-84. PubMed ID: 6827310
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical significance of quantitative antibodies measurement in blood serum by interaction with muscle acetylcholine receptor domain in myasthenia patients].
    Gekht BM; Lantsova VB; Sepp EK
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(2):34-7. PubMed ID: 12674702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia.
    Niks EH; Kuks JB; Wokke JH; Veldman H; Bakker E; Verschuuren JJ; Plomp JJ
    Muscle Nerve; 2010 Aug; 42(2):283-8. PubMed ID: 20544919
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interaction of myasthenic immunoglobulins and cholinergic agonists on acetylcholine receptors of rat myotubes.
    Ashizawa T; Elias SB; Appel SH
    Ann Neurol; 1982 Jan; 11(1):22-7. PubMed ID: 6277235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Complement-dependent lysis of cultured rat myotubes by myasthenic immunoglobulins.
    Ashizawa T; Appel SH
    Neurology; 1985 Dec; 35(12):1748-53. PubMed ID: 4069366
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release.
    Engel AG; Lambert EH; Gomez MR
    Ann Neurol; 1977 Apr; 1(4):315-30. PubMed ID: 214017
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats.
    Chamberlain-Banoub J; Neal JW; Mizuno M; Harris CL; Morgan BP
    Clin Exp Immunol; 2006 Nov; 146(2):278-86. PubMed ID: 17034580
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Myasthenia gravis. Current concepts.
    Gutmann L; Chou SM
    Arch Pathol Lab Med; 1976 Aug; 100(8):401-4. PubMed ID: 947303
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differences in acetylcholine receptor-antibody interactions between extraocular and extremity muscle fibers.
    Oda K
    Ann N Y Acad Sci; 1993 Jun; 681():238-55. PubMed ID: 8357165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experimental autoimmune myasthenia gravis: the rabbit as an animal model.
    Eldefrawi ME
    Fed Proc; 1978 Dec; 37(14):2823-7. PubMed ID: 720635
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The membrane attack complex of complement at the endplate in myasthenia gravis.
    Engel AG; Arahata K
    Ann N Y Acad Sci; 1987; 505():326-32. PubMed ID: 3318619
    [No Abstract]   [Full Text] [Related]  

  • 57. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation.
    Losen M; Martínez-Martínez P; Phernambucq M; Schuurman J; Parren PW; De Baets MH
    Ann N Y Acad Sci; 2008; 1132():174-9. PubMed ID: 18567867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.
    Loutrari H; Kokla A; Tzartos SJ
    Eur J Immunol; 1992 Sep; 22(9):2449-52. PubMed ID: 1516631
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experimental myasthenia gravis: a model of receptor disease.
    Takamori M; Kasai M
    Int J Neurol; 1980; 14(1):47-60. PubMed ID: 6293991
    [No Abstract]   [Full Text] [Related]  

  • 60. [Observation on the changes in the frequency of end-plate potentials evoked by sera with different antibodies from patients with myasthenia gravis in nerve-muscle preparation of rats].
    Lu C
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Feb; 25(1):44-6, 63. PubMed ID: 1317284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.